Jewish General Hospital Segal Cancer Centre
BREAST CLINIC
Breast Surgery Team
Our breast surgery team consists of five fellowship-trained breast surgical oncologists who specialize in the surgical management of benign and malignant breast disease. They are affiliated with the McGill University Department of Surgery and Oncology and work closely with colleagues in the Departments of Breast Radiology, Medical and Radiation Oncology, Genetics, and Plastic and Reconstructive Surgery to coordinate and oversee the clinical care of our breast cancer patients.
Mark Basik MD
Accreditations
Herbert Black Chair in Surgical Oncology
Professor, Department of Surgical and Oncology, McGill University
Senior Scientist, Lady Davis Institute for Medical Research
Head, Cancer Genomics and Translational Research Laboratory, Segal Cancer Centre
​
Post Doctoral Training
General Surgical Oncology, Roswell Park Cancer Centre, New York
NIH Visiting Investigator, National Human Genome Research Institute, Maryland
Education
MD, McGill University Medical School, Quebec
General Surgery, Université de Montréal, Quebec
Professional Recognitions and Honors
Co-chair of the NCI Breast Oncology Local Disease (BOLD) Task Force in 2016-2020
President, Scientific Advisory Committee, Canadian Cancer Research Society 2021
​
Research Focus
Mark Basik's laboratory bridges basic and clinical research to study drug resistance as well as novel tumor markers in breast cancer patients. The research focuses mainly on triple-negative breast cancers, the most aggressive breast cancer subtype. Many cancer patients inevitably develop drug resistance at some point during their treatment. Our team makes use of cutting-edge technologies and patient specimens to further understand the mechanisms behind the emergence of resistance; identify novel therapeutic targets as well as biomarkers such as circulating tumor DNA to monitor recurrence. The ultimate objective of our work is to circumvent resistance and improve cancer therapy to benefit cancer patients.
​
​
"The great thing about clinical trials is that you are always at the cutting edge. You’re always studying or involved in new treatments. It’s always pushing forward."
Jean Francois Boileau MD MSc
Accreditations
Associate Professor, Department of Surgery and Oncology, McGill University
Director, Jewish General Hospital Breast Clinical Trials Group
Post Doctoral Training
Surgical Oncology, University of Toronto, Ontario
Education
MD, Université de Montréal, Quebec
MSc Biomedical sciences (Clinical Trials), Université de Montréal, Quebec
Professional Recognitions and Honors
Principal Investigator, SN FNAC Trial, Canadian multicentre study evaluating the accuracy of sentinel node biopsy in node-positive breast cancer patients following neoadjuvant chemotherapy (JCO, 2015)
National Bank Innovation and Community Support Award
Research Focus
Clinical trials involving preoperative and adjuvant systemic therapy for the treatment of breast cancer and axillary management following neoadjuvant chemotherapy. Was the principal investigator of the SN FNAC Trial, a Canadian multi-centred study evaluating the accuracy of sentinel node biopsy in node-positive breast cancer patients following neoadjuvant chemotherapy (JCO, 2015). Current co-senior investigator for the TADEN trial evaluating Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer.
​
​
​
​
.jpg)
Karyne Martel MD
Accreditations
Assistant Professor, Department of Surgery, McGill University
​
Post Doctoral Training
Complex Surgical Oncology, McGill University Medical School, Quebec
Education
Research Focus
Karyne Martel's clinical and research interest involves incorporating level I and II oncoplastic techniques in the treatment of breast cancer to minimize the impact of surgery and optimize quality of life for patients. She has completed additional certificate training from the Society of Oncoplastic Surgery and Brazilian Society of Mastology and is a member of the International Oncoplastic Breast Consortium (OPBC).
"We have a responsibility to make sure that patients have access to the breast cancer treatment, preventative care and clinical trials they need in a timely manner regardless of their socioeconomic, cultural, or educational background."
Ipshita Prakash MD MSc
Accreditations
Assistant Professor, Departments of Surgery and Oncology, McGill University
Clinician Investigator, Lady Davis Institute for Medical Research
Director, McGill Breast Outcomes Research Group
​
​
Post Doctoral Training
Breast Surgical Oncology, Duke University, North Carolina
Education
MD, McGill University Medical School, Quebec
MSc Health Policy Planning & Financing, London School of Economics, London School of Hygiene & Tropical Medicine, United Kingdom
Research Focus
Ipshita Prakash's research program focuses on health services research, specifically breast cancer financial toxicity and disparities, as well as access to specialized care. With her research, she hopes to examine breast cancer outcomes through an inter-disciplinary lens, improve access to breast cancer care for underserved groups and eliminate disparities. She directs the McGill Breast Cancer Outcomes Group and is a founding member of the McGill Global Oncology Program. She is also part of the World Health Organization’s Global Breast Cancer Initiative to reduce global breast cancer mortality.
"It is such a privilege to treat women with breast cancer and take care of those at high risk for developing breast cancer. They are an incredibly strong and courageous patient population."
Stephanie Wong MD MPH
Accreditations
Assistant Professor, Department of Surgery and Oncology, McGill University
Clinician Investigator, Lady Davis Institute for Medical Research
Director, High Risk Breast Clinic, JGH Stroll Cancer Prevention Centre
Post Doctoral Training
Breast Surgical Oncology, Dana-Farber/Brigham and Women's and Massachusetts General Hospital, Massachusetts
Education
MD, McGill Medical School, Quebec
MPH Clinical Effectiveness, Harvard School of Public Health, Massachusetts
Professional Recognitions and Honors
Research Focus
FRQS Clinical Research Scholars Junior 1 Award (2021-2025)
QBCF Emerging Scientist Award (2022)
Stephanie Wong's research program focuses on women at increased risk for developing breast cancer, including women with a genetic susceptibility (ie. BRCA1/2, PALB2, and other carriers), women with strong family history or abnormal breast biopsies, or those who are at high-risk due to other factors. For these high-risk populations, significant gaps in knowledge exist on how to optimally lower risk while minimizing impact on one’s psychosocial and physical well-being. Her research program seeks to address these issues by comprehensively characterizing the cancers that develop in different subgroups of high-risk women and evaluate ways to optimize decision making around preventive options.